China’s first GM rice gets US FDA approval
By Bai Tiantian,
Global Times
| 01. 22. 2018
A genetically modified (GM) rice product developed by a group of Chinese scientists has acquired the US Food and Drug Administration (FDA) approval, the first such Chinese product allowed to enter the US market.
However, neither China nor the US has approved mass cultivation of the rice amid low acceptance from the Chinese public for GM food.
Huahui No.1 rice, developed by the Huazhong Agricultural University, is genetically engineered to resist a wide range of insects, thus reducing the use of pesticides.
Lin Yongjun, a professor at Huazhong Agricultural University and one of the scientists that developed the rice, told the Global Times on Monday that Huahui No.1 could not be grown in China as "the country has not conducted regional trials nor provided guidelines to examine genetically engineered rice."
Lin said his team might consider growing Huahui No. 1 in Southeast Asian countries, "but our reach is limited and we hope the authorities can provide funding and legal support."
Lin's university received an email from the FDA on January 11 approving the rice.
The email, which was made public...
Related Articles
By Kiana Jackson and Shannon Stubblefield, New Disabled South | 02.09.2026
"MC0_8230" via Wikimedia Commons licensed under CC by 2.0
This report documents a deliberate assault on disabled people in the United States. Not an accident. Not a series of bureaucratic missteps. An assault that has been coordinated across agencies...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Jonathan D. Moreno, Hastings Center Bioethics Forum | 02.09.2026
When I began to write a book about bioethics and the rules-based international order, the idea that the world was facing the greatest geopolitical change since World War II was uncontroversial for those who were paying attention to such esoterica...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...